Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA)

Geode Capital Management LLC raised its position in shares of Savara Inc (NASDAQ:SVRA) by 10.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,726,850 shares of the company’s stock after buying an additional 264,825 shares during the quarter. Geode Capital Management LLC owned about 1.59% of Savara worth $11,564,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Savara by 22.9% in the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. Frazier Life Sciences Management L.P. grew its holdings in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the period. Vestal Point Capital LP increased its stake in shares of Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after purchasing an additional 1,001,296 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after purchasing an additional 3,443,541 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 0.3 %

Shares of NASDAQ:SVRA opened at $3.07 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 1 year low of $2.82 and a 1 year high of $5.70. The company has a market cap of $526.87 million, a P/E ratio of -7.14 and a beta of 0.92. The stock’s fifty day moving average price is $3.41 and its 200-day moving average price is $3.94.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Sell-side analysts expect that Savara Inc will post -0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company initiated coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. HC Wainwright dropped their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.86.

Insider Activity

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph S. Mccracken acquired 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the purchase, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. Insiders own 5.13% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.